Tsfg LLC Has $15.27 Million Stock Holdings in Abbott Laboratories $ABT

Tsfg LLC raised its stake in Abbott Laboratories (NYSE:ABT) by 6.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 114,037 shares of the healthcare product maker’s stock after buying an additional 6,784 shares during the quarter. Abbott Laboratories comprises 2.4% of Tsfg LLC’s investment portfolio, making the stock its 9th largest position. Tsfg LLC’s holdings in Abbott Laboratories were worth $15,274,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of ABT. Carr Financial Group Corp grew its stake in shares of Abbott Laboratories by 2.0% in the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after acquiring an additional 76 shares in the last quarter. Tortoise Investment Management LLC boosted its holdings in Abbott Laboratories by 10.7% during the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after purchasing an additional 77 shares during the last quarter. Gemmer Asset Management LLC grew its position in Abbott Laboratories by 2.9% in the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after purchasing an additional 78 shares in the last quarter. Bridgewater Advisors Inc. increased its stake in Abbott Laboratories by 0.6% in the 2nd quarter. Bridgewater Advisors Inc. now owns 12,555 shares of the healthcare product maker’s stock valued at $1,607,000 after buying an additional 79 shares during the last quarter. Finally, Nia Impact Advisors LLC lifted its position in shares of Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after buying an additional 79 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $109.51 on Tuesday. The firm’s 50 day moving average is $122.41 and its 200 day moving average is $127.35. The stock has a market capitalization of $190.43 billion, a P/E ratio of 29.44, a PEG ratio of 1.74 and a beta of 0.75. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the previous year, the firm posted $1.34 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is currently 67.74%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ABT. Jefferies Financial Group increased their price target on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. The Goldman Sachs Group decreased their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Sanford C. Bernstein decreased their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Evercore ISI lowered their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $137.05.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s CEO personally invested roughly $2M while the stock has been under pressure — a management buy that signals confidence to shareholders and can help stabilize sentiment. Article Title
• Positive Sentiment: Freedom Capital upgraded ABT to a Buy (recently lowering its PT to $120), which gives the stock a retail/institutional buying narrative despite the lower target. Article Title
• Positive Sentiment: Long‑term bull case pieces note Abbott’s Dividend Aristocrat status, multi‑year revenue growth and strong balance sheet, reinforcing a buy-and-hold thesis for income/quality investors. Article Title
• Positive Sentiment: Opinion/bull-case coverage outlines structural upside from diagnostics and recurring revenue streams, offering a narrative that could attract growth‑oriented buyers. Article Title
• Neutral Sentiment: Abbott’s deal with Exact Sciences is reshaping its diagnostics footprint (strategic upside), but its nutrition business is undergoing a reset — a mixed development that likely means longer lead times before clear earnings upside. Article Title
• Neutral Sentiment: Barclays trimmed its price target from $169 to $142 but kept an Overweight rating, signaling conviction in Abbott’s story despite near-term headwinds. Article Title
• Neutral Sentiment: Valuation comparisons (e.g., Zacks piece on NVST vs ABT) highlight Abbott as a relatively lower-volatility, dividend-oriented option — useful context but not an immediate catalyst. Article Title
• Negative Sentiment: Daiwa cut its price target to $113 — a downgrade that adds selling pressure from analysts and may weigh on near‑term sentiment. Article Title
• Negative Sentiment: Leerink lowered its target to $119, another analyst haircut that contributes to a chorus of reduced near‑term expectations. Article Title

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.